S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024

PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

$49.42
+0.58 (+1.19%)
(As of 03/28/2024 ET)
Today's Range
$48.89
$50.42
50-Day Range
$45.34
$50.75
52-Week Range
$24.83
$52.32
Volume
555,752 shs
Average Volume
471,217 shs
Market Capitalization
$2.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.60

PROCEPT BioRobotics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.7% Downside
$45.60 Price Target
Short Interest
Healthy
8.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$6.15 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.00) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.13 out of 5 stars

Medical Sector

863rd out of 939 stocks

Surgical & Medical Instruments Industry

89th out of 97 stocks

PRCT stock logo

About PROCEPT BioRobotics Stock (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

PRCT Stock Price History

PRCT Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PRCT Oct 2024 55.000 call
PRCT Apr 2024 50.000 put
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
PRCT Jul 2024 70.000 call
PRCT Mar 2024 70.000 call
Q4 2023 Procept Biorobotics Corp Earnings Call
PROCEPT BioRobotics: Q4 Earnings Insights
Piper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics's Earnings: A Preview
PROCEPT BioRobotics Corporation
See More Headlines
Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/29/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PRCT
Fax
N/A
Employees
626
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.60
High Stock Price Target
$58.00
Low Stock Price Target
$37.00
Potential Upside/Downside
-7.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-105,900,000.00
Pretax Margin
-77.76%

Debt

Sales & Book Value

Annual Sales
$136.19 million
Book Value
$5.56 per share

Miscellaneous

Free Float
40,975,000
Market Cap
$2.52 billion
Optionable
Optionable
Beta
1.02
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 69)
    President, CEO & Director
    Comp: $1.26M
  • Mr. Kevin Waters (Age 47)
    Executive VP & CFO
    Comp: $744.1k
  • Ms. Alaleh Nouri (Age 45)
    EVP, Chief Legal Officer & Corporate Secretary
    Comp: $713.61k
  • Mr. Hisham Shiblaq (Age 48)
    Executive VP & Chief Commercial Officer
    Comp: $757.2k
  • Mr. Mohan F. Sancheti (Age 60)
    Senior Vice President of Operations
  • Mr. Barry Templin
    Executive VP of Technology & Clinical Development
  • Mr. Matthew James Bacso C.F.A.
    Vice President of Investor Relations
  • Ms. Stacey L. Porter (Age 48)
    Chief People Officer
  • Mr. Bijesh Chandran
    Senior Vice President of Regulatory Affairs & Quality Assurance

PRCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings
or view top-rated stocks.

What is PROCEPT BioRobotics' stock price target for 2024?

6 Wall Street research analysts have issued 1-year target prices for PROCEPT BioRobotics' stock. Their PRCT share price targets range from $37.00 to $58.00. On average, they predict the company's stock price to reach $45.60 in the next twelve months. This suggests that the stock has a possible downside of 7.7%.
View analysts price targets for PRCT
or view top-rated stocks among Wall Street analysts.

How have PRCT shares performed in 2024?

PROCEPT BioRobotics' stock was trading at $41.91 on January 1st, 2024. Since then, PRCT shares have increased by 17.9% and is now trading at $49.42.
View the best growth stocks for 2024 here
.

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our PRCT earnings forecast
.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.10. The firm had revenue of $43.58 million for the quarter, compared to analysts' expectations of $41.79 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 46.59% and a negative net margin of 77.75%. The firm's quarterly revenue was up 83.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.56) earnings per share.

What ETFs hold PROCEPT BioRobotics' stock?
What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million.

When did PROCEPT BioRobotics IPO?

PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.29%), Vanguard Group Inc. (8.21%), Price T Rowe Associates Inc. MD (2.98%), Price T Rowe Associates Inc. MD (2.98%), Wellington Management Group LLP (2.09%) and Bellevue Group AG (1.75%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends
.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRCT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners